共 326 条
[1]
Chiou VL(2015)Pseudoprogression and immune-related response in solid tumors J Clin Oncol 33 3541-3543
[2]
Burotto M(2004)CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings AJR Am J Roentgenol 183 1619-1628
[3]
Choi H(2007)Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753-1759
[4]
Charnsangavej C(2013)Breakthrough of the year 2013. Cancer immunotherapy Science 342 1432-1433
[5]
de Castro Faria S(2015)Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes J Immunol 194 950-959
[6]
Tamm EP(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[7]
Benjamin RS(2013)Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N Engl J Med 369 134-144
[8]
Johnson MM(2014)Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients Nature 515 563-567
[9]
Macapinlac HA(2010)Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 711-723
[10]
Podoloff DA(2014)Baseline tumor size as an independent prognostic factor for overall survival in patients with metastatic melanoma treated with the anti-PD-1 monoclonal antibody MK-3475 ASCO Meeting Abstracts 32 3015-440